Pfizer and BioNTech Release Vaccine Early Look
Pfizer and German mRNA biotech partner BioNTech have released an early look at their experimental pandemic vaccine, and the news is good.
The pair’s mRNA-based vaccine candidate, BNT162b2, has shown in its closely watched phase 3 that it was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.
This is a big deal, given that most saw 50% to 70% effectiveness as a strong win; 90% is likely the best case for the vaccine, and Pfizer cautioned that as more data come in, this could change. The data are based on a two-shot dosing schedule, and the 90% figure comes 28 days after the initial dose.